InSilico Medicine Cayman TopCo (HKG:3696)
Hong Kong · Delayed Price · Currency is HKD 52.55
-0.45 (-0.85%)
Sep 10, 2026, 11:15 AM HKT
HKG:3696 Revenue
InSilico Medicine Cayman TopCo had revenue of $106.30M USD in the half year ending June 30, 2026, with 78.09% growth. This brings the company's revenue in the last twelve months to $135.09M, up 152.02% year-over-year. In the year 2025, InSilico Medicine Cayman TopCo had annual revenue of $56.24M, down -34.48%.
Revenue (ttm)
$135.09M
Revenue Growth
+152.02%
P/S Ratio
28.81
Revenue / Employee
$405.66K
Employees
333
Market Cap
30.52B HKD
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 56.24M | -29.60M | -34.48% |
| Dec 31, 2024 | 85.83M | 34.65M | 67.71% |
| Dec 31, 2023 | 51.18M | 21.03M | 69.77% |
| Dec 31, 2022 | 30.15M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
InSilico Medicine Cayman TopCo News
- 2 days ago - Insilico's Co-CEO Has Big Hopes That Fibrosis Drug Can Reverse Aging Too - WSJ
- 7 days ago - Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain - PRNewsWire
- 14 days ago - InSilico Medicine Cayman TopCo Earnings Call Transcript: Q2 2026 - Transcripts
- 14 days ago - InSilico Medicine Cayman TopCo Earnings release: Q2 2026 - Filings
- 14 days ago - InSilico Medicine Cayman TopCo Slides: Q2 2026 - Filings
- 26 days ago - Insilico Medicine Introduces Biological Age into Virtual Cell Research: Launches Virtual Aging Cell Webpage and Previews Multi-Agent Driven VAC Generation Platform - PRNewsWire
- 4 weeks ago - Insilico Medicine Nominates ISM0900, a Potent, AI-driven, Oral Lp(a) Inhibitor, as PCC for Management of Cardiovascular Risks - PRNewsWire
- 4 weeks ago - Insilico Medicine Announces 2026 Interim Earnings Conference Call Dates - PRNewsWire